GlobeNewswire Inc.··Inmune Bio Inc.INmune Bio's Alzheimer's Trial Wins Spotlight as Model for Inflammation-Targeting Approach
INmune Bio's XPro trial gains recognition at AD/PD 2026 for innovative biomarker-enriched Alzheimer's approach, securing FDA approval to advance to Phase 2b/3 registrational studies.
INMBclinical trialAlzheimer's disease